CCCC - Company ID 0001662579
C4 Therapeutics, Inc. trades as CCCC. In its fiscal 2025 annual report the company posted revenue of $35.95M, up 1.0% from the prior year and net income of -$104.99M. This page tracks C4 Therapeutics, Inc. through 514 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 4 fiscal years C4 Therapeutics, Inc.'s revenue declined from $45.78M to $35.95M, a compound annual decline rate of 5.9%. Net profit margin compressed from -183.2% to -292.1% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G | - | 2026-05-19 |
| Major company event | 8-K | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-12 |
| Major company event | 8-K | 2026-05-12 |
| Annual report to shareholders | ARS | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-29 |
The largest companies sharing C4 Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
C4 Therapeutics, Inc. reported revenue of $35.95M for fiscal year 2025, an increase of 1.0% year over year.
In its latest fiscal year C4 Therapeutics, Inc. reported a net loss of $104.99M.